MicroRNA-133b is a Key Promoter of Cervical Carcinoma Development Through the Activation of the ERK and AKT1 Pathways.

W. Qin,P. Dong,C. Ma,K. Mitchelson,T. Deng,L. Zhang,Y. Sun,X. Feng,Y. Ding,X. Lu,J. He,H. Wen,J. Cheng
DOI: https://doi.org/10.1038/onc.2011.561
IF: 8.756
2012-01-01
Oncogene
Abstract:We report that elevated microRNA-133b (miR-133b) acts as an oncogene in human cervical carcinoma to promote tumorigenesis and metastasis. In situ hybridization confirmed that miR-133b is localized in proliferating human cervical carcinoma cells with levels progressively elevating throughout advancing stages. Cellular studies showed that miR-133b enhances cell proliferation and colony formation by targeting mammalian sterile 20-like kinase 2 (MST2), cell division control protein 42 homolog (CDC42) and ras homolog gene family member A (RHOA), which subsequently results in activation of the tumorigenic protein kinase B alpha (AKT1) and mitogen-activated protein kinase (ERK1 and ERK2, here abbreviated as ERK) signaling pathways. Mouse experiments revealed that upregulation of miR-133b in cervical carcinoma cells strongly promotes both in vivo tumorigenesis and independent metastasis to the mouse lung. The data indicates that upregulation of miR-133b shortens the latency of cervical carcinoma. Together, these findings suggest that miR-133b could be a potent marker for the early onset of cervical carcinoma. Oncogene (2012) 31, 4067-4075; doi: 10.1038/onc.2011.561; published online 19 December 2011
What problem does this paper attempt to address?